"We appreciate the support our bank group has provided Barr over the years and view their willingness to agree to this amendment as further evidence of the strength of this combination," said Bill McKee, EVP and CFO of Barr.
Teva expects the acquisition to close by late 2008.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit http://www.barrlabs.com.
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
The statements, analyses and other information contained herein
relating to the proposed merger, financing, anticipated synergies, savings
and financial and operating performance, including estimates for growth,
trends in each of Teva Pharmaceutical Industries Ltd.'s and Barr
Pharmaceutical, Inc.'s operations and financial results, the markets for
Teva's and Barr's products, the future developmen
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved